Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eslicarbazepine acetate - Bial

Next Previous
X
Search
Drug Profile

Eslicarbazepine acetate - Bial

Alternative Names: Aptiom; BIA 2-093; ESL; Eslicarbazepine; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bial
  • Developer BIAL; Eisai Co Ltd; Sumitomo Pharma America; Whanin Pharmaceutical
  • Class Acetates; Amides; Analgesics; Antiepileptic drugs; Antimigraines; Dibenzazepines; Esters; Mood stabilisers; Small molecules
  • Mechanism of Action T-type calcium channel antagonists; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase II Epilepsy; Migraine
  • Discontinued Bipolar disorders; Fibromyalgia; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 28 Sep 2022 No recent reports of development identified for phase-I development in Partial-epilepsies(In volunteers) in South Korea (PO, Tablet)
  • 10 May 2021 Registered for Partial epilepsies (Monotherapy) in Australia (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top